By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing ...

Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Her parents encouraged her to partake in a trial for a CRISPR -based therapy for sickle-cell disease and beta-thalassemia, another debilitating genetic blood disorder. The therapy, Casgevy, was made ...

Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes.

The approval of Vertex and partner CRISPR Therapeutics CRSP one-shot gene therapy Casgevy for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), has ...